Navigation Links
Positron's Attrius Receives Health Canada Approval
Date:12/14/2011

FISHERS, Ind., Dec. 14, 2011 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce today that on December 12, 2011, the Company's Positron Emission Tomography Scanner(s) Attrius & Attrius L have received approval for sale in Canada.

The Medical Device License from Health Canada was granted to the Attrius systems manufacturer, Neusoft Positron Medical Systems. NPMS is a joint venture between Neusoft Medical Systems of Shenyang, China and Positron Corporation. Positron Corporation has exclusive rights to sell Attrius in North America.    

"We are pleased that our scanners are approved for the Health Canada system. It is great step forward for our technology and our integrated PET solutions," said Patrick G. Rooney, CEO of Positron.  "The Canadian market is vast with a sophisticated approach to health care and is a market that requires the full cardiac PET solution. We have developed leading products and are integrating key segments critical to being able to offer the complete value chain.  The Canadian market is very important to us and we intend to have a very strong presence throughout the country."   

About Positron: Positron Corporation is a leading molecular imaging company providing innovative nuclear medicine technologies and services that are reshaping the field of nuclear cardiology.  Through proprietary PET imaging systems and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine.  Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Positron Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik
2. Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure
3. ULURU Inc. Receives Notice From NYSE Amex Regarding Continued Listing Standards
4. GPs PerformTech Division Receives Prestigious MarCom Award
5. Boston Scientific Receives FDA Approval for New Infinion™ 16 Percutaneous Lead for Precision Plus™ Spinal Cord Stimulator System
6. Assured Pharmacy, Inc. Receives Gross Proceeds of $740,000 from Sale of Convertible Debentures and Warrants
7. Unity Management Group, Inc. Receives Contract From Sun Pharmaceutical Indias Largest Pharmaceutical Companies for $105,000
8. DATATRAK Receives CDISC Registered Solutions Provider Status
9. China Health Resource Receives Letter of Intent for DAR Totaling About $8 Million
10. MiMedx Group Receives HCPCS C-Code from Medicare for EpiFix® Reimbursement
11. Inova Labs Receives CE Mark Approval for the LifeChoice® Portable Oxygen Concentrator System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):